7.17 +0.14 (1.99%)
After hours: 6:24PM EST
|Bid||7.17 x 4000|
|Ask||7.25 x 900|
|Day's Range||6.81 - 7.11|
|52 Week Range||4.86 - 13.21|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.08|
CLEVELAND, Jan. 7, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change. This resulted in total fourth quarter 2018 revenue of approximately $21 million, compared to fourth quarter 2017 revenue of $19.9 million, primarily from four revenue units.
CLEVELAND, Jan. 4, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today the enrollment of the first patient in the Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial, a multi-center, prospective clinical trial for locally advanced or borderline pancreatic cancer. The trial will explore the clinical benefits of precise, high dose radiation therapy enabled by MR-guidance combined with daily on-table adaptation in the treatment of pancreatic cancer. Retrospective analysis of precise, high-dose MR-guided radiation therapy delivered using adaptive dose planning has shown promising results with locally advanced pancreatic cancer, suggesting the potential for improving overall survival relative to patients receiving lower radiation doses, without increasing the rate of serious gastrointestinal toxicity. The compelling nature of the retrospective data prompted the SMART trial, aimed at investigating in a controlled, prospective manner, the robustness of this outcome and tracking quality of life over a 5-year trial period.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
CLEVELAND , Dec. 10, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California . ...
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CLEVELAND , Nov. 21, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today the appointment of Robert M. Fuchs ...
CLEVELAND , Nov. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that company management is scheduled to participate in a fireside chat at the 30 th Annual Piper Jaffray Healthcare ...
President & CEO of Viewray Inc (NASDAQ:VRAY) Scott William Drake bought 60,000 shares of VRAY on 11/13/2018 at an average price of $6.47 a share.
The Oakwood Village, Ohio-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring costs and severance costs, came to 25 cents per share. The results missed Wall Street ...
CLEVELAND , Nov. 8, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) ("the Company") today announced financial results for the third quarter ended September 30, 2018 . Third Quarter 2018 Highlights: ...
CLEVELAND, Oct. 29, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK, Spain and Australia, to introduce the first MRIdian MRI-guided radiotherapy system in the UK to benefit cancer patients.
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The meeting featured presentations highlighting clinical experiences with the MRIdian System from leading radiation oncologists at the Moffitt Cancer Center and David Geffen School of Medicine at UCLA. A presentation by Louis B. Harrison, M.D., FASTRO, Chair and Senior Member, Department of Radiation Oncology at Moffitt Cancer Center, highlighted the opportunity for MRI-guided radiotherapy in the treatment of cancer and its potential contribution to personalizing radiation therapy including emerging areas of interest such as optimization of treatment through an adaptive therapy loop and diffusion weighted imaging to predict tumor response.
CLEVELAND , Oct. 18, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2018 financial results, which will take place after the market ...
Presentations to Highlight Clinical Value of World's Only FDA-Cleared MRI-guided Radiotherapy System CLEVELAND , Oct. 16, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's ...
Leading Oncologists to Highlight MRIdian MRI-Guided Adaptive Radiotherapy, Discuss Emergence as a New Potential Standard of Cancer Care CLEVELAND , Oct. 9, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) ...
Investors are always looking for growth in small-cap stocks like ViewRay Inc (NASDAQ:VRAY), with a market cap of US$890m. However, an important fact which most ignore is: how financially healthy Read More...
CLEVELAND, Oct. 2, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the appointment of James "Jim" Alecxih as Chief Commercial Officer, effective September 17th, 2018. Mr. Alecxih joins the ViewRay leadership team with extensive experience in commercializing new and innovative devices globally and will be responsible for driving the Company's commercial expansion. Prior to joining ViewRay, Mr. Alecxih served as Vice President of Worldwide Sales at Nevro, where he led the high-growth neuromodulation device company's commercial efforts across multiple geographies. Mr. Alecxih also spent 14 years at Intuitive Surgical, where he served most recently as Senior Vice President of Sales for North America, South America, Australia and New Zealand.
CLEVELAND, Oct. 1, 2018 /PRNewswire/ -- Leading oncology experts from around the world met to discuss the integration of magnetic resonance imaging (MRI) with radiation therapy and its potential to extend life expectancy and reduce common side effects in many cancer patients. ViewRay, Inc. (VRAY), maker of MRIdian®, the world's first and only FDA-cleared, MRI-guided radiation therapy system, and Miami Cancer Institute, co-hosted experts from research hospitals at the cutting-edge of cancer treatment at the September 28 symposium and panel discussion.
ViewRay (VRAY) incurred general and administrative expenses of $10.5 million in the second quarter compared to $7.46 million in the second quarter of 2017. Its selling and marketing expenses increased from $1.87 million in the second quarter of 2017 to $3.39 million in the second quarter of 2018 due to an increase in its head count to support its growing sales efforts.
In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating. The mean rating for ViewRay stock is a 2, and its target price is $12.71, implying an upside potential of 30.8% over its closing price of $9.72 on September 27. In comparison, for peers Intuitive Surgical (ISRG), Medtronic (MDT), and Zimmer Biomet Holdings (ZBH), analysts have mean ratings of 2.06, 2.24, and 2.25, respectively, and target prices of $565.8, $102.45, and $136.39, respectively.